ScholarLens Back to search
2013•Journal for ImmunoTherapy of CancerOpen access

Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival

Joseph R. Broucek, Tasha M. Hughes, Erica J. Huelsmann, Joseph L Poshepny, Carl E. Ruby, Andrew Zloza, Howard L. Kaufman

Open full text 0 citations

Abstract

Meeting abstracts Combination immunotherapy is quickly gaining attention in the field of cancer treatment. IL-2, a cytokine which activates T cells, and ipilimumab, a monoclonal antibody that blocks CTLA-4, are both approved as monotherapy for metastatic melanoma. To date, combination immunotherapy

Open-access reader

About this research paper

What this paper is about

Meeting abstracts Combination immunotherapy is quickly gaining attention in the field of cancer treatment. IL-2, a cytokine which activates T cells, and ipilimumab, a monoclonal antibody that blocks CTLA-4, are both approved as monotherapy for metastatic melanoma. To date, combination immunotherapy

Why it matters

A significance statement is not available in the OpenAlex record.

Key contribution

A contribution statement is not available in the OpenAlex record.

Method / approach

Method details are not available in the OpenAlex metadata.

Main findings

Findings are not separately available in the OpenAlex metadata.

Limitations

Limitations are not available in the OpenAlex metadata.

Applications

Application details are not available in the OpenAlex metadata.

Available abstract

Meeting abstracts Combination immunotherapy is quickly gaining attention in the field of cancer treatment. IL-2, a cytokine which activates T cells, and ipilimumab, a monoclonal antibody that blocks CTLA-4, are both approved as monotherapy for metastatic melanoma. To date, combination immunotherapy

Key concepts: Ipilimumab, Medicine, Immunotherapy, CTLA-4, Blockade, Monoclonal antibody, Metastatic melanoma, Cancer immunotherapy

Related papers

Related paper 1Related paper 2Related paper 3
Back to paper searchBrowse research topicsOriginal source
Combination immunotherapy with Interleukin-2 and CTLA-4 blockade decreases tumor growth and improves overall survival — Research Paper | ScholarLens